xGen® Acute Myeloid Leukemia Cancer Panel

The xGen® AML Cancer Panel v1.0 provides 11,743 individually synthesized and quality controlled xGen Lockdown® Probes to achieve deep enrichment of targets from more than 260 genes associated with the AML disease pathway.

Benefits

  • High uniformity with 98% of genomic targets covered at greater than 0.2 x mean coverage
  • Detect variations reliably with high reproducibility and increased depth of coverage
  • Faster time to result with validated functionality using an IDT optimized 4-hour hybridization protocol
  • Highly relevant for AML-related applications due to empirically derived targets
  • Fast turnaround via easy online ordering and next day shipping

Features

  • Individually synthesized and quality controlled lockdown probes
  • 11,743 xGen® Lockdown Probes targeting regions within 260 genes
  • Targets defined by whole genome and exome sequencing of 200 AML patients
  • Compatible with the IDT optimized xGen 4-hour Capture Protocol

xGen® Acute Myeloid Leukemia Cancer Panel v1.0

The xGen® AML Cancer Panel v1.0 provides 11,743 individually synthesized and quality controlled xGen Lockdown® Probes to achieve deep enrichment of targets from more than 260 genes associated with the AML disease pathway.

ProductPricing
16 rxn xGen® AML Cancer Panel v1.0$2,500.00 USD
96 rxn xGen® AML Cancer Panel v1.0$8,500.00 USD

Optimized for Acute Myeloid Leukemia Sequencing Applications

ASXL1 FAM154B IDH2 KDR NPM1 PRAMEF2
C17orf97 FAM47A JAK1 KIT NRAS PTPN11
CBL FAM5C JAK2 KRAS NTRK3 RUNX1
CEBPA FLRT2 JAK3 LRRC4 OR13H1 TET2
DNMT3A FLT3 KCNA4 MLL3 OR8B12 TP53
EGFR GJB3 KCNK13 MYC P2RY2 TUBA3C
EZH2 IDH1 KDM6A NF1 PCDHB1 WT1

Table 1. Frequently Researched Genes Included in the xGen® AML Cancer Panel. The panel does not target every exon in each gene, but targets all regions found to be mutated in the TCGA study. For a complete list of genes, click here.

High Coverage Uniformity

Figure 1. Excellent Coverage Uniformity Obtained with xGen® Lockdown AML Cancer Panel. Greater than 0.2 x mean coverage is observed for >98% of targets. Libraries were prepared using the Illumina TruSeq® LT chemistry and sequenced on a MiSeq system using 250 x 250 paired-end reads. A cumulative of 31.8M reads was generated for all four samples.

Increased Throughput and Greater Sensitivity with Deep Coverage

Figure 2. Deep Coverage of Targeted Regions Using xGen® AML Cancer Panel. Four TruSeq® genomic DNA libraries were enriched using the xGen® Acute Myeloid Leukemia Cancer Panel and sequenced on a MiSeq system using 250 x 250 paired-end reads. A total of 31.8M reads were generated. In all samples, there was >1X coverage for 99.8% of targets and >30X coverage for 99.2–99.4% of targets.

Consistent Performance with High Reproducibility

Figure 3. Excellent Reproducibility Obtained with xGen® AML Cancer Panel. Multiplexed samples prepared with Illumina TruSeq® libraries were sequenced on the MiSeq sequencing platform using 250 x 250 paired-end reads. A comparison of probe-by-probe target coverage between two samples showed excellent reproducibility, with an R2 value of 0.9831.

References

  1. Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368(22):2059–2074